91 related articles for article (PubMed ID: 2924328)
1. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.
Kauppila A; Puistola U; Risteli J; Risteli L
Cancer Res; 1989 Apr; 49(7):1885-9. PubMed ID: 2924328
[TBL] [Abstract][Full Text] [Related]
2. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
3. Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer.
Santala M; Risteli J; Kauppila A
Anticancer Res; 2004; 24(2C):1057-62. PubMed ID: 15154623
[TBL] [Abstract][Full Text] [Related]
4. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer.
Simojoki M; Santala M; Risteli J; Kauppila A
Gynecol Oncol; 2001 Jul; 82(1):110-5. PubMed ID: 11426971
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Kauppila A
Ann Med; 1990 Apr; 22(2):115-21. PubMed ID: 2361007
[TBL] [Abstract][Full Text] [Related]
6. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
7. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma.
Tomás C; Risteli J; Risteli L; Vuori J; Kauppila A
Obstet Gynecol; 1991 Apr; 77(4):566-72. PubMed ID: 2002979
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Vuori J; Kauppila A
Cancer; 1990 Dec; 66(11):2399-406. PubMed ID: 2245396
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma.
Tomás C; Kauppila A
Gynecol Oncol; 1992 Jun; 45(3):279-83. PubMed ID: 1612504
[TBL] [Abstract][Full Text] [Related]
10. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
11. Measurement of epithelial and stromal changes in vulvar carcinoma - a clinical, biochemical and immunohistochemical study.
Tomas C; Risteli J; Risteli L; Stenback F; Kauppila A
Int J Oncol; 1995 Jul; 7(1):101-5. PubMed ID: 21552813
[TBL] [Abstract][Full Text] [Related]
12. Analytical, physiologic, and clinical validation of a radioimmunoassay for measurement of procollagen type III amino terminal propeptide in serum and bronchoalveolar lavage fluid obtained from dogs.
Schuller S; Valentin S; Remy B; Jespers P; Foulon S; Van Israël N; Clercx C; McEntee K
Am J Vet Res; 2006 May; 67(5):749-55. PubMed ID: 16649905
[TBL] [Abstract][Full Text] [Related]
13. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology.
Jensen LT
Dan Med Bull; 1997 Feb; 44(1):70-8. PubMed ID: 9062765
[TBL] [Abstract][Full Text] [Related]
14. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.
Risteli L; Risteli J; Puistola U; Tomás C; Zhu GG; Kauppila A
Acta Obstet Gynecol Scand Suppl; 1992; 155():99-103. PubMed ID: 1502898
[TBL] [Abstract][Full Text] [Related]
15. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients.
Teppo AM; Törnroth T; Honkanen E; Grönhagen-Riska C
Transplantation; 2003 Jun; 75(12):2113-9. PubMed ID: 12829921
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic values of type III Procollagen N-terminal peptide and combination assay of type III procollagen N-terminal peptide with CEA and CA 19-9 in gastric cancer].
Akazawa S; Harada A; Futatsuki K
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1434-8. PubMed ID: 6588922
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
18. Type III procollagen N-peptide correlates with beta-2-microglobulin in myelomatosis.
Hasselbalch HC; Bjerrum OW; Junker P
Clin Lab Haematol; 1995 Sep; 17(3):237-41. PubMed ID: 8719897
[TBL] [Abstract][Full Text] [Related]
19. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
Zhu GG; Risteli J; Puistola U; Kauppila A; Risteli L
Cancer Res; 1993 Oct; 53(20):5028-32. PubMed ID: 8402695
[TBL] [Abstract][Full Text] [Related]
20. CA-125 monitoring in the management of ovarian cancer.
Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
